Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTS-412 Immune Dynamics in a Healthy Volunteer
NCT07302945Phase 1Completed
- Sponsor
- Bionoxx
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OTS-412 in cancer, sponsored by Bionoxx. Primary endpoints: Absolute Neutrophil Count at Day 16 and Lymphocyte Count at Day 16. Started Jan 2022; status: completed.
02
Drugs
OTS-412
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07302945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07302945.